After a disappointing fourth quarter, Exelixis(NASDAQ: EXEL) reaccelerated growth in the first quarter, bolstered by a new approval for Cabometyx in previously untreated advanced renal cell carcinoma (RCC), also known as kidney cancer.
Exelixis Reaccelerates Growth
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться